Unveiling the Role of IL-10-Neutralising Autoantibodies in Pediatric-Onset Inflammatory Bowel Disease: Prevalence, Persistence, and Clinical Implications

Highlight

• IL-10-neutralising autoantibodies were identified in approximately 2% of pediatric-onset IBD patients without known monogenic causes.
• These autoantibodies persist longitudinally under standard immunosuppressive therapies but disappear following hematopoietic stem-cell transplantation (HSCT).
• Presence of IL-10 neutralising autoantibodies may represent a unique immunological subtype with distinct clinical features and treatment considerations in pediatric IBD.
• Screening for IL-10 autoantibodies via functional assays could guide personalized management strategies in this patient population.

Study Background